Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry

Abstract

Background:

Being overweight increases the risk of cardiovascular diseases and mortality. However, among high-body-weight patients with established acute coronary syndrome (ACS) this evidence is not clear. In this scenario, a low body weight (LBW) has been proposed to confer higher prognostic risk and higher bleeding risk with new P2Y₁₂ inhibitors.

Aims:

We aimed to examine differences in mortality, catheterizations/revascularizations, antiplatelet therapy and ischemic/bleeding adverse events between ACS patients with LBW.

Methods:

This is a multicenter registry involving 1576 consecutive ACS patients (ST-elevation myocardial infarction (STEMI), non-STEMI, or unstable angina) from three tertiary institutions. Patients were divided into two groups: LBW (weight < 60 kg, n = 176) and non-LBW (weight ⩾ 60 kg, n = 1400). During 12 months follow-up, we recorded management (catheterizations/revascularizations), antiplatelet therapy, major adverse cardiovascular events (MACEs), bleeding events (BARC classification), and mortality.

Results:

Catheterizations (86.4% vs. 93.4%; p = 0.001) and revascularizations (64.8% vs. 76.1%; p = 0.001) were significantly lower in the LBW group. At discharge, prescription of new P2Y₁₂ inhibitors was also lower in LBW patients (24.4% vs. 37.8%; p = 0.001). After 12-month follow-up, the incidence of MACE (HR 1.61 (95% CI 1.03–2.50]; p = 0.038) and mortality (HR 2.18 (95% CI 1.33–3.58); p = 0.002) was higher in LBW patients compared with non-LBW. In contrast, there were no significant differences for bleeding events.

Conclusions:

LBW in ACS patients was associated with higher incidence of MACE and mortality. In this group of patients less catheterizations and coronary revascularizations were performed. Despite there being no differences in bleeding rates, new P2Y₁₂ inhibitors were less prescribed in LBW patients.

Keywords

Acute coronary syndrome body weight hemorrhage ischemia platelet aggregation inhibitors

Get full access to this article

View all access options for this article.

References

Lavie

Milani

Ventura

. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925–1932.

Lavie

McAuley

Church

. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol 2014; 63: 1345–1354.

Eckel

Jakicic

Ard

. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S76–S99.

Hainer

Aldhoon-Hainerova

. Obesity paradox does exist. Diabetes Care 2013; 36(Suppl 2): S276–S281.

Niedziela

Hudzik

Niedziela

. The obesity paradox in acute coronary syndrome: a meta-analysis. Eur J Epidemiol 2014; 29: 801–812.

Jakubowski

Riesmeyer

. TRITON and beyond: new insights into the profile of prasugrel. Cardiovasc Ther 2012; 30: e174–e182.

Wiviott

Braunwald

McCabe

. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.

Mehran

Rao

Bhatt

. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736–2747.

Angeras

Albertsson

Karason

. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J 2013; 34: 345–353.

10.

Das

Alexander

Chen

. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 2011; 58: 2642–2650.

11.

Lavie

De Schutter

Parto

. Obesity and prevalence of cardiovascular diseases and prognosis: the obesity paradox updated. Prog Cardiovasc Dis 2016; 58: 537–547.

12.

Perk

De Backer

Gohlke

. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–1701.

13.

Romero-Corral

Montori

Somers

. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006; 368: 666–678.

14.

Bucholz

Rathore

Reid

. Body mass index and mortality in acute myocardial infarction patients. Am J Med 2012; 125: 796–803.

15.

Herrmann

Gersh

Goldfinger

. Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol 2014; 114: 9–16.

16.

Hastie

Padmanabhan

Slack

. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J 2010; 31: 222–226.

17.

Oreopoulos

Padwal

Norris

. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. Obesity 2008; 16: 442–450.

18.

Reeves

Ascione

Chamberlain

. Effect of body mass index on early outcomes in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2003; 42: 668–676.

19.

Simoons

Windecker

. Controversies in cardiovascular medicine: chronic stable coronary artery disease: drugs vs. revascularization. Eur Heart J 2010; 31: 530–541.

20.

Wijns

Kolh

Danchin

. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501–2555.

21.

Jayasinghe

Markham

Adsett

. Dual antiplatelet therapy: management in general practice. Aust Fam Physician 2013; 42: 702–705.

22.

Kushner

Hand

Smith

Jr . 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271–2306.

23.

Stone

Witzenbichler

Weisz

. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614–623.

24.

Tsukahara

Kimura

Morita

. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J 2010; 74: 679–685.

25.

Wallentin

Becker

Budaj

. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.

26.

Kulik

Ruel

Jneid

. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation 2015; 131: 927–964.

27.

Alexopoulos

Xanthopoulou

Deftereos

. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry. J Thromb Haemost 2016; 14: 1146–1154.

28.

Roffi

Patrono

Collet

. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267–315.

29.

Steg

James

Atar

. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.

30.

Capodanno

Ferreiro

Angiolillo

. Antiplatelet therapy: new pharmacological agents and changing paradigms. J Thromb Haemost 2013; 11(Suppl 1): 316–329.

31.

Navarese

Verdoia

Schaffer

. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM 2011; 104: 561–569.

32.

Saito

Isshiki

Kimura

. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 2014; 78: 1684–1692.

33.

Erlinge

Ten Berg

Foley

. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol 2012; 60: 2032–2040.

34.

Zeymer

Widimsky

Danchin

. P2Y₁₂ receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. Eur Heart J Cardiovasc Pharmacother 2016; 2: 229–243.

35.

Lindholm

Varenhorst

Cannon

. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J 2014; 35: 2083–2093.

36.

Siller-Matula

Krumphuber

Jilma

. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 2010; 159: 502–517.

37.

European Medicines Agency (EMA). Brilique (ticagrelor): summary of product characteristics. London: European Medicines Agency.